A phase I/II study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients (pts) with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)

被引：0
|
作者：
Palou, J. [1 ]
Marcq, G. [2 ]
Steinberg, G. [3 ]
Toscone, C. [4 ]
Sullivan, J. [4 ]
Linback, T. [4 ]
Pruthi, R. [4 ]
Bryce, R. [4 ]
Brown, G. [5 ]
机构：
[1] Fundacio Puigvert, Dept Urol, Barcelona, Spain
[2] CHU Lille, Urol, Ctr Hosp Reg Univ Lille, Lille, France
[3] Rush Univ, Urol, Coll Med, Chicago, IL USA
[4] EnGene Inc, Clin Dev, Waltham, MA USA
[5] Summit Hlth Jefferson Hlth New Jersey, Urol Dept, Voorhees, NJ USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2023TiP
引用
收藏
页码：S1165 / S1165
页数：1
相关论文
共 50 条
  • [1] A phase 1/2 study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
    Bryce, Richard
    Tosone, Christine
    Sullivan, James C.
    Linback, Tammy
    Steinberg, Gary D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] LEGEND, A PHASE 1/2 STUDY OF DETALIMOGENE VORAPLASMID (EG-70) INTRAVESICAL MONOTHERAPY DEMONSTRATED CLINICAL RESPONSES IN BCG-UNRESPONSIVE NMIBC PATIENTS WITH CIS
    Gary, Steinberg
    Susan, Kolata
    Yair, Lotan
    Christine, Tosone
    Rosemary, Mazanet
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S48 - S48
  • [3] A phase 1/2 study of detalimogene voraplasmid (EG-70) intravesical monotherapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC).
    Chang, Sam S.
    Dickstein, Rian J.
    Jayram, Gautam
    Shore, Neal D.
    Liu, Jen-Jane
    Lotan, Yair
    Satkunasivam, Raj
    Schuckman, Anne K.
    Steinberg, Gary D.
    Taylor, John R.
    Linback, Tammy
    Pruthi, Raj
    Sullivan, James C.
    Tosone, Christine
    Kamat, Ashish M.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS886 - TPS886
  • [4] EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: Preclinical characterization and translation into the clinic
    Goulet, Marie-Line
    Dauphinee, Shauna M.
    Veilleux, Daniel
    Louis, Kristine S.
    Lazure, David
    Stevenson, Sarah
    Bilimoria, Darius
    Zamzameer, Fazmina
    Chen, Ximin
    Sublemontier, Sebastien
    Amirkhani, Sahar
    Fleet, Carlos
    Bryce, Richard
    Bui, Matthew
    Joshi, Shreyas
    Kalota, Susan J.
    Cheung, Anthony
    Sullivan, James
    CLINICAL CANCER RESEARCH, 2024, 30 (10)
  • [5] Clinical results of a phase 1 study of intravesical EG-70 in patients with BCG-unresponsive NMIBC.
    Steinberg, Gary D.
    Kalota, Susan J.
    Lotan, Yair
    Warner, Loraine
    Dauphinee, Shauna
    Mazanet, Rosemary
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] AN INTERIM ANALYSIS OF A PHASE II CLINICAL STUDY OF INTRAVESICAL PHOTO DYNAMIC THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS)
    Kulkarni, Girish
    Richards, Kyle
    Black, Peter C.
    Rendon, Ricardo
    Chin, Joseph
    Shore, Neal
    Jayram, Gautam
    Kramolowsky, Eugene
    Saltzstein, Daniel
    Agarwal, Piyush
    Belkoff, Laurence
    O'Donnell, Michael
    Kamat, Ashish M.
    Zlotta, Alexandre
    Jewett, Michael A. S.
    Lamm, Donald
    DeGruttola, Victor
    Mandel, Arkady
    Dumoulin-White, Roger J.
    Kassouf, Wassim
    JOURNAL OF UROLOGY, 2023, 209 : E871 - E871
  • [7] HYPERTHERMIC INTRAVESICAL CHEMOTHERAPY FOR BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
    de Jong, Joep
    Hendricksen, Kees
    Rosier, Marloes
    Boormans, Joost
    Mostafid, Hugh
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1234 - E1235
  • [8] Phase II trial of intravesical camrelizumab in BCG-unresponsive high-risk non-muscle invasive bladder cancer
    Shen, Yijun
    Peng, Liangju
    Xu, Peihang
    Wang, Yanhao
    Wang, Xiang
    Yao Xudong
    Liu, Yushan
    Ye, Ding-Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
    Narayan, V.
    Boorjian, S.
    Alemozaffer, M.
    Konety, B. R.
    Gomella, L.
    Kamat, A. M.
    Lerner, S. P.
    Svatek, R. S.
    Karsh, L.
    Canter, D.
    Lotan, Y.
    Inman, B. A.
    Yang, M.
    Garcia-Horton, V.
    Sawutz, D.
    Parker, N.
    Dinney, C. P. N.
    EUROPEAN UROLOGY, 2021, 79 : S1026 - S1027
  • [10] A phase I study of intravesical camrelizumab for BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC)
    Wang, Y.
    Xu, P. H.
    Bian, X. J.
    Lu, X. L.
    Wang, Z.
    Wang, X.
    Yao, X. D.
    Shen, Y. J.
    Ye, D. Y.
    EUROPEAN UROLOGY, 2022, 81 : S251 - S251
12345